<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>6</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>06</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Diagnostic and Clinical Significance of KIT(CD117) Expression in Thymic Epithelial Tumors in China</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2745</FirstPage>
			<LastPage>2748</LastPage>
			<ELocationID EIdType="pii">26569</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Aims: To study KIT (CD117) expression in thymic epithelial tumors in China, and investigate diagnosticand clinical significance. Material and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Thymic epithelial tumors (TETs) from 102 patients (3 type A,29 type AB, 5 type B1, 22 type B2, 29 typeB3 and 16 thymic carcinomas) were examined. Immunohistochemicalstaining with an antic-kit monoclonal antibody was performed on a tissue microarray. Relationships betweenKIT positive expression and the TET clinical characteristics (WHO histologic classification and Masaoka stagesystem) were analysed. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: The KIT positive expression rate was significantly higher in thymic carcinoma(60%, 9/16) than in thymoma (8%, 7/86), a strong correlation being found with the WHO classification, but notthe Masaoka tumor stage. The overall survival for patients with KIT positive lesions was significantly worse.&lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: KIT is a good molecule marker to differentially diagnose thymic carcinoma from thymoma, whilealso serving as a predictor of prognosis for TETs. Further research into KIT mutations in Chinese TETs shouldbe conducted to assess the efficacy of targeted therapy.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">thymoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">thymic carcinoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">thymic epithelial tumors</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">KIT</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_26569_8ce7b1b484feef814e09b6860b871050.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
